TMPRSS-13 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human TMPRSS-13 (UniProt Q9BYE2), expressed in HEK293 cells. Type II transmembrane serine protease used in activity assays, inhibitor IC50 determination, substrate cleavage studies, and antibody validation.
Expression system
HEK293
Cat. #
REC-TMPRSS13

In stock

SKU
REC-TMPRSS13
$498.00

Target Overview

TMPRSS-13 (UniProt Q9BYE2; gene TMPRSS13) is a type II transmembrane serine protease belonging to the mosaic serine protease subgroup of the TTSP family. The full-length human protein spans 586 amino acids and is anchored at the cell membrane, with its catalytic serine protease domain oriented extracellularly. This recombinant form is produced in HEK293 cells, a mammalian expression system that supports the native disulfide bonding and glycosylation patterns characteristic of TTSP-family ectodomains — properties important for physiologically relevant enzymatic activity in vitro. Documented substrates include the proform of PRSS8/prostasin, which TMPRSS-13 cleaves to generate active prostasin, and the proform of hepatocyte growth factor (HGF), activation of which promotes downstream MAPK signaling. These cleavage events place TMPRSS-13 at biologically significant nodes in epithelial homeostasis and growth factor processing. Researchers use this recombinant in fluorogenic peptide-substrate activity assays to confirm and characterise catalytic function, and in inhibitor screening formats to determine IC50 values for candidate serine protease inhibitors — including peptidomimetics and small molecules under investigation as broad-spectrum host-directed antivirals. The protein is also used as a positive-control antigen in Western blot and immunohistochemistry antibody validation workflows. Researchers requiring a validated antibody matched to this recombinant can pair SKU REC-TMPRSS13 with the Triple Point Biologics TMPRSS-13 antibody (RP-TMPRSS13), which has been validated for Western blot against human target. Predicted cross-reactivity with monkey and pan-species orthologs provides additional flexibility for comparative studies.

Background

TMPRSS-13 (Transmembrane Protease Serine 13; also described as Membrane-Type Mosaic Serine Protease) is a member of the type II transmembrane serine protease (TTSP) family. Like other TTSPs — including TMPRSS2, TMPRSS11D, and matriptase — TMPRSS-13 is anchored at the plasma membrane and exerts its proteolytic activity in the pericellular environment. Its catalytic activity (EC 3.4.21.-) has been characterised against two physiologically relevant substrates: the zymogen form of PRSS8/prostasin, whose activation by TMPRSS-13 participates in epidermal serine protease cascades, and the single-chain precursor of hepatocyte growth factor (HGF), cleavage of which generates the active α/β heterodimer and potentiates MAPK signaling. In developing embryos, TMPRSS-13 activity has been linked (by sequence and functional homology) to formation of the stratum corneum and establishment of the epidermal barrier. Beyond its roles in epithelial biology, TMPRSS-13 has attracted research attention as a host cell protease relevant to viral entry. Several TTSP-family members — most prominently TMPRSS2, but also TMPRSS13 — are capable of priming viral spike or envelope proteins, and TMPRSS-13 has been studied in this context for SARS-CoV-2 and other respiratory pathogens. Banas et al. (2026, Biochem J) examined inhibition of transmembrane serine proteases including TMPRSS-13 as a strategy for broad-spectrum antiviral drug development, highlighting the enzyme as a relevant target in inhibitor profiling panels. Structural and mechanistic studies of closely related family members — such as the crystallographic characterisation of TMPRSS11D autocleavage reported by Fraser et al. (2025, Nat Commun) — provide structural frameworks applicable to understanding TMPRSS-13 activation and active-site architecture. In the inhibitor discovery space, TMPRSS-13 is routinely included alongside TMPRSS2 and matriptase in selectivity panels for peptidomimetic and small-molecule candidates. Its inclusion in such panels reflects the practical need to differentiate on-target inhibition from broader TTSP-family activity. Recombinant TMPRSS-13 expressed in a mammalian system is the preferred reagent for this purpose, as bacterial or insect-cell-derived material can lack the post-translational modifications required for native-like activity and substrate recognition. Triple Point Biologics has supported proteinase and inhibitor research with recombinant proteins and matched antibodies since 1994.

Applications

  • Fluorogenic peptide-substrate activity assay to confirm catalytic serine protease function
  • Inhibitor IC50 determination in small-molecule and peptidomimetic TTSP-family selectivity panels
  • Prostasin (PRSS8) zymogen cleavage assay to characterise substrate activation kinetics
  • HGF precursor cleavage assay coupled with downstream MAPK signaling readouts
  • Western blot positive-control antigen for validation of anti-TMPRSS-13 antibodies (pairs with RP-TMPRSS13)
  • IHC standard for antibody titration and specificity confirmation in human tissue sections
  • Broad-spectrum antiviral host-protease inhibitor profiling panel component
  • Biophysical characterisation (thermal shift, SPR) of inhibitor or substrate binding to the TMPRSS-13 ectodomain

References

  1. Banas V et al. Towards broad-spectrum antiviral drugs: inhibition of transmembrane serine proteases. Biochem J. 2026. doi:10.1042/BCJ20250335. PMID: 41847980.
  2. Végh B et al. Efficient production of fully active, SARS-CoV-2-priming, wildtype TMPRSS2 ectodomain via co-expression of HAI-2 allows for both auto- and cross-activation mechanisms. Biochem J. 2025. doi:10.1042/BCJ20253453. PMID: 41408854.
  3. Wang Y et al. TMEM106B Supports Viral Entry and Syncytia Formation Mediated by the Spike Proteins From Omicron BA.2.86 and JN.1. J Med Virol. 2025. doi:10.1002/jmv.70439. PMID: 40556423.
  4. Fraser BJ et al. Structural basis of TMPRSS11D specificity and autocleavage activation. Nat Commun. 2025. doi:10.1038/s41467-025-59677-3. PMID: 40348740.
  5. Lemieux G et al. From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants. J Med Chem. 2025. doi:10.1021/acs.jmedchem.4c02468. PMID: 40163818.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Type II transmembrane serine protease; cell surface

Frequently Asked Questions

What is the expected molecular weight of recombinant TMPRSS-13 on SDS-PAGE or Western blot?

The full-length human TMPRSS-13 protein (UniProt Q9BYE2) has a predicted molecular weight of ~66 kDa based on its 586-amino-acid sequence. Due to N-linked glycosylation introduced during HEK293 expression — which mirrors the native glycosylation pattern of the TTSP ectodomain — the apparent MW on reducing SDS-PAGE typically runs between 70–80 kDa. If you are running non-reducing conditions, disulfide-stabilized conformers may shift the band further. Always compare against a prestained ladder calibrated in the 50–100 kDa range.

What processing or isoform state is this TMPRSS-13 recombinant — zymogen or activated form?

This recombinant is produced as the catalytically active ectodomain of TMPRSS-13, encompassing the serine protease domain. TMPRSS-13 belongs to the mosaic serine protease subgroup of the TTSP family and undergoes autocatalytic or trans-activation cleavage at a conserved Arg/Lys site in the activation loop. The HEK293 expression system supports the disulfide bonding required for proper domain folding; however, the precise zymogen-to-active ratio in the final lot is confirmed by activity assay before release. A certificate of activity is available on request.

What substrates does TMPRSS-13 cleave and which fluorogenic peptide substrate should I use in a activity assay?

TMPRSS-13 documented biological substrates include the proform of PRSS8/prostasin and the proform of HGF — both cleaved at basic residue motifs. For in vitro fluorogenic assays, Boc-Gln-Ala-Arg-AMC and Tos-Gly-Pro-Arg-AMC are suitable trypsin-like serine protease substrates and have been used with closely related TTSPs. Start at 100–200 µM substrate concentration with 0.5–2 µg/mL recombinant TMPRSS-13 in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl). Monitor AMC release at Ex 360 nm / Em 460 nm. Titrate enzyme concentration to keep initial velocity in the linear range.

What is the recommended assay buffer and pH for TMPRSS-13 protease activity in vitro?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — serves as a practical starting point for activity assays. TMPRSS-13 is a serine protease with preference for basic residues (Arg/Lys at P1), and its activity is generally optimal near physiological pH (7.4–8.0). Avoid EDTA, which is not required for this serine protease but is non-inhibitory; standard serine protease inhibitors (PMSF, AEBSF, benzamidine) must be excluded from assay buffers. BSA (0.01–0.1%) can be added to reduce non-specific surface adsorption in low-enzyme-concentration experiments.

How do I determine a starting concentration of TMPRSS-13 recombinant for an IC50 inhibitor screening experiment?

For IC50 measurements, the enzyme concentration should be well below the Ki of the tightest inhibitor you intend to rank — typically 0.5–2 nM total active enzyme — to avoid tight-binding artefacts (Cheng-Prusoff applies). Convert the supplied protein concentration (µg/mL) to molar using the apparent MW of ~70–75 kDa. Run a substrate titration (Km determination) first using the Boc-Gln-Ala-Arg-AMC or equivalent substrate, then set substrate at ~Km for IC50 experiments. This ensures the measured IC50 is easily corrected to Ki using the standard competitive inhibition equation.

Can I use REC-TMPRSS13 as a positive control antigen on Western blot with the matched TPB antibody RP-TMPRSS13?

Yes — this is one of the primary intended uses of the pairing. REC-TMPRSS13 and the rabbit polyclonal antibody RP-TMPRSS13 are produced and validated in the same laboratory, guaranteeing epitope compatibility. Load 20–50 ng of REC-TMPRSS13 per lane on a 10% SDS-PAGE gel under reducing conditions; RP-TMPRSS13 should detect the ~70–80 kDa glycosylated band cleanly. This positive control is especially useful when validating antibody lot-to-lot consistency or when setting up TMPRSS-13 detection in a new cell lysate panel. See the RP-TMPRSS13 product page (/anti-tmprss-13-rabbit-polyclonal-antibody) for recommended dilutions.

How much recombinant TMPRSS-13 should I load as a Western blot positive control to get a clean band?

20–50 ng per lane is the recommended starting range when using RP-TMPRSS13 at standard working dilutions. At 20 ng you should obtain a detectable band without saturating the signal; 50 ng provides a robust reference band suitable for molecular weight confirmation alongside cell lysates. Use reducing SDS-PAGE sample buffer; boiling for 5 min at 95°C is appropriate. The glycosylated band will appear at approximately 70–80 kDa. If running alongside high-protein-content tissue lysates, load the recombinant in a dedicated lane rather than mixing, to avoid signal interference.

How should I store and handle REC-TMPRSS13 to preserve enzymatic activity — can I refreeze unused protein?

REC-TMPRSS13 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol in single-use aliquots and should be stored at -20°C. Repeated freeze-thaw cycles measurably reduce serine protease activity — even one additional cycle can result in 20–30% activity loss in our experience with TTSP-family ectodomains. Thaw each aliquot on ice, use what you need, and discard the remainder rather than refreezing. If you anticipate multiple uses within a week, a working aliquot may be kept at 4°C for up to 5–7 days; add BSA to 0.1 mg/mL to stabilize dilute preparations.

Validation imagery coming soon

Western blot validation figures for REC-TMPRSS13 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →